查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552540

美國女性醫療保健市場規模、佔有率、趨勢分析報告：按應用、年齡、藥物和細分市場預測，2024-2030

U.S. Women's Health Market Size, Share & Trends Analysis Report By Application (Contraceptives, Endometriosis & Uterine Fibroids), By Age (50 Years & Above, Others), By Drug (Prolia, XGEVA), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

美國女性醫療保健市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，美國女性保健市場規模預計將達到296.8億美元，2024年至2030年複合年成長率為4.04%。

目標疾病盛行率的上升是市場成長的主要驅動力。預計隨著人口老化和肥胖的增加，骨關節炎的盛行率將會增加。導致女性荷爾蒙失調的主要因素包括飲食變化、壓力和飲酒，這些都可能導致不孕。排卵障礙、多囊性卵巢症候群（PCOS）和子宮內膜異位症是不孕的主要原因。

增加對計劃生育服務的公共資金進一步推動市場成長。據估計，美國每年約有 45% 的懷孕是意外懷孕。儘管避孕技術取得了進步，避孕藥具的研發支出也有所增加，美國的意外懷孕率幾十年來一直沒有改變。這增加了低收入群體的經濟負擔，因為他們無法輕易獲得現代、更有效的避孕方法。因此，聯邦和州政府正在積極努力改善獲得計劃生育服務和現代避孕器的機會。例如，2019年，美國政府向聯合國人口基金提供了6.08億美元資金，用於計劃生育和生殖健康發展。

此外，童婚在低度開發經濟體和新興經濟體中最為常見，常導致早期意外懷孕。此外，避孕意識淡薄，使得問題更加嚴重。根據聯合國兒童基金會的數據，過去十年童婚現象減少了 15%。然而，在美國，這個數字多年來並沒有減少，因為美國一些州有法律允許18歲以下結婚。然而，該國正在努力解決童婚及其對婦女醫療保健的影響，包括倡導政策變革、促進女孩教育、提高對童婚負面影響及其對婦女健康影響的認知。支援服務。

此外，參與各種治療藥物開發和配製的主要公司都專注於合作研究和建立夥伴關係，以開發新藥並保持市場競爭力。例如，2022年10月，Solera Health宣布推出全球首個女性健康網路數位點解決方案，解決女性健康問題的需求。此外，2022 年 11 月，Sebella Pharmaceuticals 宣布推出一個完全致力於女性醫學的新部門。

美國女性醫療保健市場報告亮點

  • 從藥物來看，Prolia 藥物細分市場在 2023 年佔據了最大的收益佔有率，預計在預測期內將以最快的複合年成長率成長，因為它作為一種副作用很少的藥物被廣泛採用。
  • 從應用來看，由於人們對計劃生育的認知不斷提高，預計避孕藥具領域在預測期內將呈現最快的複合年成長率。
  • 從年齡來看，到2023年，其他年齡層將主導美國女性用醫藥產業，因為子宮內膜異位症、荷爾蒙性不孕症和多囊性卵巢症候群等不孕問題在該年齡層中呈上升趨勢。
  • 從分銷管道來看，由於醫院藥房的女性用健康治療產品庫存充足且供應充足，醫院藥房細分市場將在 2023 年佔據市場主導地位。
  • 領先的市場參與企業不斷關注產品發布和地理擴張，以維持自己的地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章美國女性醫療保健市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 美國女性保健市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 價格分析

第4章美國女性保健市場：按應用估算和趨勢分析

  • 2023年及2030年市場佔有率
  • 細分儀表板
  • 美國女性醫療保健市場前景：按應用分類
  • 2018-2030年市場規模、預測及趨勢分析
    • 荷爾蒙不孕症
    • 避孕藥
    • 停經後骨質疏鬆症
    • 子宮內膜異位症和子宮肌瘤
    • 閉經
    • 卵巢症候群（PCOS）

第5章美國女性保健品市場：依藥品分類的預估及趨勢分析

  • 2023年及2030年市場佔有率
  • 細分儀表板
  • 美國女性醫療保健市場前景：按藥物分類
  • 2018-2030年市場規模、預測及趨勢分析

第6章美國女性保健市場：依年齡估計及趨勢分析

  • 2023年及2030年市場佔有率
  • 細分儀表板
  • 美國女性醫療保健市場前景：按年齡層別分類
  • 2018-2030年市場規模、預測及趨勢分析

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • AbbVie, Inc.
    • Bayer AG
    • Merck &Co., Inc.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Agile Therapeutics
    • Amgen, Inc.
    • Apothecus Pharmaceutical Corp.
    • Eli Lilly and Company
    • Ferring BV
Product Code: GVR-4-68040-106-9

U.S. Women's Health Market Growth & Trends:

The U.S. women's health market size is expected to reach USD 29.68 billion by 2030, expanding at a CAGR of 4.04% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of target diseases is a key driver for the growth of the market. With aging and the increasing prevalence of obesity, the prevalence of osteoarthritis is anticipated to grow. Some of the major factors responsible for hormonal imbalance in women include changes in dietary habits, stress, and consumption of alcohol, which can cause fertility issues. Ovulation problems, polycystic ovarian syndrome (PCOS), and endometriosis are major factors responsible for infertility.

The rise in public funding for family planning services is further driving the market growth. In the U.S., approximately 45% of pregnancies are estimated to be unwanted every year. Despite advancements in contraceptive technology and increased R&D spending on contraceptives, the rate of unplanned pregnancies in the U.S. has remained unchanged for decades. This has increased the economic burden on low-income families that do not have easy access to modern and more effective methods of contraception. Hence, federal & state governments are actively working toward improving family planning services and access to modern contraceptives. For instance, in 2019, the U.S. government provided USD 608 million in funding to UNFPA for family planning & reproductive health development.

Moreover, child marriages are most common in underdeveloped and developing economies, often leading to early and unplanned pregnancies. There is a lack of awareness about contraceptives, which amplifies the severity of the problem. According to UNICEF, child marriages decreased by 15% in the past decade. However, the number has not decreased over the years in the U.S. because laws in certain U.S. states allow marriages before 18 years. However, efforts to address child marriage and its impact on women's health are being undertaken in the country, which involve advocating for policy changes, promoting girls' education, raising awareness about the negative consequences of child marriage, and providing support services for affected girls and women.

Furthermore, key players involved in developing and formulating various therapeutics are focusing on collaborations and partnerships to develop novel drugs and maintain their competitive position in the market. For instance, in October 2022, Solera Health announced the launch of first-of-its-kind digital point solutions for women's Health networks to address women's health issues needs. Moreover, in November 2022, Sebela Pharmaceuticals announced the launch of a new division fully dedicated to women's health.

U.S. Women's Health Market Report Highlights:

  • Based on drug, the Prolia drug segment held the largest revenue share in 2023 and is anticipated to grow at the fastest CAGR over the forecast period owing to the wide adoption of the drug with very less side effects
  • Based on application, the contraceptives segment is expected to showcase the fastest CAGR over the forecast period, owing to an increase in awareness about family planning
  • Based on age, the others age segment dominated the U.S. women's health industry in 2023, due to the rising concerns of fertility, such as endometriosis, hormonal infertility, and PCOS in this age group
  • Based on distribution channel, the hospital pharmacy segment dominated the market in 2023 due to the high stock and availability of women's health therapeutics in the hospital pharmacies
  • Key market players are constantly focusing on product launches and geographical expansion to maintain their presence

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Age
    • 1.2.3. Drug
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database.
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. Age outlook
    • 2.2.3. Drug outlook.
  • 2.3. Competitive Insights

Chapter 3. U.S. Women's Health Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of target diseases
      • 3.2.1.2. Increasing initiatives by government and various organizations
      • 3.2.1.3. Rising publicly funded family planning services
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiry of major drugs
      • 3.2.2.2. Lawsuits related to products.
      • 3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices.
  • 3.3. U.S. Women's Health Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. U.S. Women's Health Market: Application Estimates & Trend Analysis

  • 4.1. Application Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Women's Health Market by Application Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Hormonal infertility
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Contraceptives
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Postmenopausal osteoporosis
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Endometriosis & uterine fibroids
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Menopause
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Polycystic ovary syndrome (PCOS)
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Women's Health Market: Drug Estimates & Trend Analysis

  • 5.1. Drug Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Women's Health Market by Drug Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. ACTONEL
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. YAZ, Yasmin, Yasminelle
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. FORTEO
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Minastrin 24 Fe
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Mirena
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. NuvaRing
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. ORTHO TRI-CY LO
      • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.8. Premarin
      • 5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.9. Prolia
      • 5.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.10. Reclast/Aclasta
      • 5.4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.11. XGEVA
      • 5.4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.12. Zometa
      • 5.4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.13. Others
      • 5.4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Women's Health Market: Age Estimates & Trend Analysis

  • 6.1. Age Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Women's Health Market by Age Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. 50 years and above
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2. Postmenopausal osteoporosis
        • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3. Endometriosis & uterine fibroids
        • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.4. Menopause
        • 6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.5. Others
        • 6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Others
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. AbbVie, Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Bayer AG
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Merck & Co., Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Pfizer, Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Teva Pharmaceutical Industries Ltd.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Agile Therapeutics
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Amgen, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Apothecus Pharmaceutical Corp.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Eli Lilly and Company
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Ferring B.V.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. Women's Health Market, by application, 2018 - 2030 (USD Million)
  • Table 3 U.S. Women's Health Market, by drug, 2018 - 2030 (USD Million)
  • Table 4 U.S. Women's Health Market, by age, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Women's Health Market: market outlook
  • Fig. 10 Women's health competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Women's Health Market driver impact
  • Fig. 16 U.S. Women's Health Market restraint impact
  • Fig. 17 U.S. Women's Health Market strategic initiatives analysis
  • Fig. 18 U.S. Women's Health Market: Application movement analysis
  • Fig. 19 U.S. Women's Health Market: Application outlook and key takeaways
  • Fig. 20 Hormonal infertility market estimates and forecast, 2018 - 2030
  • Fig. 21 Contraceptives estimates and forecast, 2018 - 2030
  • Fig. 22 Postmenopausal osteoporosis market estimates and forecast, 2018 - 2030
  • Fig. 23 Endometriosis & uterine fibroids estimates and forecast, 2018 - 2030
  • Fig. 24 Menopause market estimates and forecast, 2018 - 2030
  • Fig. 25 Polycystic ovary syndrome (PCOS) estimates and forecast, 2018 - 2030
  • Fig. 26 U.S. Women's Health Market: Drug movement analysis
  • Fig. 27 U.S. Women's Health Market: Drug outlook and key takeaways
  • Fig. 28 ACTONEL market estimates and forecast, 2018 - 2030
  • Fig. 29 YAZ, Yasmin, Yasminelle estimates and forecast, 2018 - 2030
  • Fig. 30 FORTEO market estimates and forecast, 2018 - 2030
  • Fig. 31 Minastrin 24 Fe estimates and forecast, 2018 - 2030
  • Fig. 32 Mirena market estimates and forecast, 2018 - 2030
  • Fig. 33 NuvaRing estimates and forecast, 2018 - 2030
  • Fig. 34 ORTHO TRI-CY LO market estimates and forecast, 2018 - 2030
  • Fig. 35 Premarin estimates and forecast, 2018 - 2030
  • Fig. 36 Prolia market estimates and forecast, 2018 - 2030
  • Fig. 37 Reclast/Aclasta estimates and forecast, 2018 - 2030
  • Fig. 38 XGEVA market estimates and forecast, 2018 - 2030
  • Fig. 39 Zometa estimates and forecast, 2018 - 2030
  • Fig. 40 Others estimates and forecast, 2018 - 2030
  • Fig. 41 U.S. Women's Health Market: Age movement Analysis
  • Fig. 42 U.S. Women's Health Market: Age outlook and key takeaways
  • Fig. 43 50 years and above market estimates and forecasts, 2018 - 2030
  • Fig. 44 Postmenopausal osteoporosis market estimates and forecasts,2018 - 2030
  • Fig. 45 Endometriosis & uterine fibroids market estimates and forecasts,2018 - 2030
  • Fig. 46 Menopause market estimates and forecasts,2018 - 2030
  • Fig. 47 Others market estimates and forecasts, 2018 - 2030
  • Fig. 48 Others market estimates and forecasts, 2018 - 2030
  • Fig. 49 Market share of key market players - U.S. Women's Health Market